Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus PSORCON E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus PSORCON E.
CAPEX vs PSORCON E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid